A phase II trial of dosage escalation of sorafenib in Asian patients with metastatic renal cell carcinoma - Abstract

AIM: To investigate the role of sorafenib dosage escalation in Asian patients with metastatic renal cell carcinoma that had progressed after routine dosages.

PATIENTS & METHODS: Sorafenib dosage escalation to 600 or 800 mg twice a day was offered to 41 patients with metastatic renal cell carcinoma who had progressed on normal dosages. Clinical outcome, toxicity and favorable clinical covariables for progression-free survival (PFS) were evaluated.

RESULTS: The median PFS with dosage-escalated therapy was 7 months. Drug-related adverse events were tolerable. The pre-escalation Karnofsky performance status, serum calcium concentration, neutrophil/lymphocyte ratio, PFS and the highest toxicity grade at the routine dosage were associated with a longer PFS in the dosage-escalation period.

CONCLUSION: Sorafenib dosage escalation was efficacious and tolerable in Asian patients.

Written by:
Wang HK, Zhang HL, Zhu Y, Yao XD, Zhang SL, Dai B, Shen YJ, Zhu YP, Shi GH, Qin XJ, Ma CG, Lin GW, Xiao WJ, Ye DW.   Are you the author?
Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.

Reference: Future Oncol. 2014 Oct;10(12):1941-51.
doi: 10.2217/fon.14.131

PubMed Abstract
PMID: 25386811

Go "Beyond the Abstract" - Read an article written by the authors for UroToday.com

UroToday.com Renal Cancer Section